Coordinator Prof Frank Barry has had a busy few months in 2019 sharing news and updates on the ADIPOA-2 project. Audiences include scientists, clinicians, biotech industrialists and patient organizations.Read more
Last week, Dr Yves-Marie Pers was an invited speaker at the University of Los Andes in Santiago, Chile. There, he delivered a talk entitled “Osteoarthritis and immunomodulation with stem cells” to a group of 40 researchers. ADIPOA-2 was acknowledged in the presentation.
Congratulations to the team of Maxime Ruiz, Karine Toupet, Marie Maumus, Pauline Rozier, Christian Jorgensen and Daniéle Noel for the publication of the paper “TGFBI secreted by mesenchymal stromal cells ameliorates osteoarthritis and is detected by extracellular vesicles.” The open access paper published in Biomaterials 226 (2020) 119544 was made available online on 11 October 2019.
Read the paper here. https://doi.org/10.1016/j.biomaterials.2019.119544
ADIPOA-2 PI Yves-Marie Pers, M.D., PhD. of INSERM Montpellier gave an oral presentation at the International Society for Cell and Gene Therapy (ISCT) meeting in Mexico City on 23 October 2019. The title of his talk was “Mesenchymal stem cells: from bench to bedside” where ADIPOA-2 was presented and acknowledged. Approximately 200 people attended Yves’ talk. The ISCT South and Central America Regional Forum took place on October 21-23, 2019.
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives. ISCT Members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.
The ADIPOA-2 consortium met for a plenary meeting on September 3, 2019, in Dublin.
This was a critical meeting to assess progress, obstacles and achievements in the ADIPOA2 clinical trial. Every partner in the clinical, manufacturing and scientific arenas was represented. Some key points have emerged during this project summit meeting on which all the partners are in strong agreement: there has been a great deal of progress in implementing the clinical trial at orthopaedic hospitals across Europe. For all of these hospitals, this is an innovative and ground-breaking technology and requires a multidisciplinary and coordinated approach, which has been successfully achieved. In addition, a multinational clinical trial such as this requires a comprehensive approach in terms of regulatory affairs in several European countries, as well as the implementation of harmonised protocols. This has all been achieved and a great deal has been learned about regulatory strategies for cellular therapies in Europe. On another level, complex manufacturing protocols have been put in place and validated in GMP facilities in France, Ireland and Germany.
“We have been able to advance the progression of complex cell therapies across Europe and learned valuable lessons about clinical trial implementation, national and harmonised approaches to the regulation of manufacturing and clinical testing. We have a consortium of partners from France, Germany, Italy, Ireland, Netherlands and UK that is strongly aligned and everyone shares the same vision and determination of delivering innovative therapies to patients. We have opened up strong opportunities for commercialisation and we expect to see the fruits of this in the near future. Because of the support projects such as this receive from Horizon programmes, there is every reason to predict that Europe will continue to be a global leader in cell therapy”.
Congratulations to the ADIPOA-2 team at the Istituto Ortopedico Rizzoli di Bologna for their latest publication in the Journal of Orthopaedic Research: “Osteoarthritic milieu affects adipose-derived mesenchymal stromal cells”. The research was conducted by the team of C Manferdini, F Paolella, E Gabusi, L Cattini, M Rojewski, H Schrezenmeier, O Addimanda, R Meliconi, G Lisignoli.
Read the entire list of ADIPOA-2 acknowledged publications here.
ADIPOA-2 researchers at the Rizzoli Orthopaedic Institute in Bologna, Dr Gina Lisignoli and Dr Cristina Manferdini of the Laboratory di Immuno-rheumatology and Tissue Regeneration have presented two ADIPOA-2 studies at the 10th Stem Cell Research Italy meeting. Hosted in Napoli, the meeting took place on June 5-7, 2019.
Dr Manfredini was awarded the first prize for the best poster presentation. Congratulations, Cristina!
Read the article in Italian in the IOR Rizzoli July 2019 newsletter on page 2 here.
The HRB Clinical Research Facility Galway in Ireland hosted a public event to celebrate International Clinical Trials Day on May 20th 2019. Exhibition stands were on display and informational meetings were held throughout the day to inform the public of all areas of clinical research being undertaken at the facility.
A particular stand was dedicated to the CRF Galway’s stem cell work to inform the public of the cell therapy projects the CRF Galway are undertaking with partners within the National University of Ireland Galway and with European partners. ADIPOA-2 was showcased here, as were related projects VISICORT and NEPHSTROM.
Dr Veronica McInerney comments, “Great interest was expressed in this evolving therapeutic area with approximately 100 members of the public stopping by to hear about what cell therapy involves and to learn about the projects from the clinical researchers on the day.”
The study “IL-1β-mediated activation of adipose-derived mesenchymal stromal cells results in PMN reallocation and enhanced phagocytosis. A possible mechanism for the reduction of osteoarthritis pathology” by the team of Stephanie C.M. van Dalen, Arjen B. Blom, Birgitte Walgreen, Annet W. Slöetjes, Monique M.A. Helsen, Edwin J.W. Geven, Thomas Vogl, Johannes Roth, Fons A.J. van de Loo, Marije I. Koenders, Louis Casteilla, Peter M. van der Kraan, Martijn H.J. van den Bosch, Peter L.E.M. van Lent was recently published in Frontiers in Immunology.
Congratulations to our team at Radboud University Medical Centre Nijmegen pictured below!
Download the pdf here.
Our partners at the Centre for Cell Manufacturing Ireland (CCMI) based at the National University of Ireland Galway have organized a workshop series: “Selection, Validation and Implementation of Rapid Microbiological Methods for ATMPs“. This event will take place in Galway, Ireland on the 12th and 13th of June 2019.
For more information, download the flyer here.
- Prof Frank Barry, NUI Galway presents ADIPOA-2 across 8 international foraOctober 29, 2019 - 8:52 am
- INSERM PI Dr Yves-Marie Pers presents ADIPOA-2 at U of Los Andes in ChileOctober 25, 2019 - 9:34 am
- ADIPOA-2 publication in Biomaterials journalOctober 24, 2019 - 10:38 am
- ADIPOA-2 presented by PI Yves-Marie Pers at ISCT 2019 in MexicoOctober 24, 2019 - 10:06 am
- Pintail hosts ADIPOA-2 plenary meeting, 3 September 2019 in DublinOctober 3, 2019 - 9:31 am
- New ADIPOA-2 publication from Istituto Ortopedico Rizzoli di BolognaAugust 29, 2019 - 12:33 pm
- IOR researchers present ADIPOA-2 at Stem Cell Research Italy meeting; Dr Manferdini takes first prizeAugust 28, 2019 - 5:54 pm
- International Clinical Trials Day 2019, GalwayJune 10, 2019 - 11:02 am
- Radboud University Medical Centre publish ADIPOA-2 studyMay 28, 2019 - 9:25 am
- ADIPOA-2 work featured in Italian health magazine “Viversani”March 25, 2019 - 1:55 pm
- Rizzoli Orthopaedic Institute researchers present ADIPOA-2 widelyMarch 25, 2019 - 8:44 am
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643809. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.